


# Senegal

# **Region: West Africa**

## Key information on co-financing

- Gross National Income per capita (2017):
- Co-financing status (2019): Initial self-financing Country is projected to enter preparatory transition phase in



### **Immunisation financing**

<b>_</b>	_									
_		2013		2014	2015		2016		2017	
Vaccines used in routine immunisation										
<ul> <li>Government expenditure</li> </ul>	\$	2,012,336	\$	2,216,761	\$	1,954,000	\$	1,854,949	\$	2,021,879
- Total expenditure	\$	7,547,336	\$	26,905,649	\$	13,804,500	\$	14,222,355	\$	6,433,995
- Government as % of total		27%	8%		14%	13%		31%		
Routine immunisation	+									
<ul> <li>Government expenditure</li> </ul>	\$	2,893,668	\$	2,216,761	\$	1,954,000	\$	31,585,826	\$	10,176,155
<ul> <li>Total expenditure</li> </ul>	\$	19,291,120	\$	26,905,649	\$	17,703,565	\$	47,029,092	\$	13,416,071
<ul> <li>Government as % of total</li> </ul>		15%		8%		11%		67%		76%
- Government as 70 of total		13/0		0 70		11/0		01 /6		


Source: WHO-UNICEF Joint Reporting Form 2017

Domestic General government expenditure on health as a share of gross domestic product:

3%

Source: WHO National Health Accounts, 2015

# **Expenditure on routine** immunisation in 2017



#### **Gavi supported vaccines**

Vaccines	Type	Year(s) of Gavi support	Co-financing required
HepB mono	Routine	2004	No
Pentavalent	Routine	2005-present	Yes
Meningitis A	Campaign	2012	No
Measles-Rubella	Campaign	2013 - 2017	No
PCV	Routine	2013-present	Yes
Measles	Routine	2014-present	No
Rotavirus	Routine	2014-present	Yes
HPV	Demonstration	2014-2015	No
IPV	Routine	2015-present	No
HPV	Routine	2018 - present	Yes


### **Co-financing payments**

	Total amount paid by the country		Co-fina	anced vaccines			
2009	\$	330,000	Penta	-	-		
2010	\$	350,000	Penta	-	-		
2011	\$	328,000	Penta	-	-		
2012	\$	343,000	Penta	-	-		
2013	\$	503,000	Penta	-	PCV		
2014	\$	976,000	Penta	Rota	PCV		
2015	\$	1,170,000	Penta	Rota	PCV		
2016	\$	1,305,000	Penta	Rota	PCV		
2017	\$	564,000	Penta	Rota	PCV		
2018	\$	1,613,000	Penta	Rota	PCV	HPV	

## **Co-financing obligations for 2019**

	Co-financ (in US\$)	ing obligations	Co-financing obligations (in doses)	
Pentavalent	\$	324,000		455,000
Rota	\$	291,000		126,000
PCV	\$	323,500		108,400
HPV	\$	194,500		42,700
Total	<b>\$</b>	1,133,000		

## Co-financing projections for 2020 - 2024



	2020	2021	2022	2023	2024
HPV national	\$ 41,704	\$ 261,193	\$ 268,124	\$ 160,111	\$ 192,016
MenA Routine	\$ 165,672	\$ 95,080	\$ 112,197	\$ 132,488	\$ 156,464
Penta	\$ 280,326	\$ 161,859	\$ 190,943	\$ 225,412	\$ 266,129
PCV	\$ 280,326	\$ 692,025	\$ 816,672	\$ 963,871	\$ 1,137,624
Rota	\$ 223,442	\$ 336,899	\$ 397,455	\$ 469,020	\$ 553,496
Total	\$ 991,468	\$ 1,547,055	\$ 1,785,391	\$ 1,950,902	\$ 2,305,728

- Projections are based on Gavi's operational forecast version 16.These projections do not guarantee renewal of support or approval of country's application.
- Final co-financing obligations will be communicated through decision letters.